Introduction: Why Pituicytoma Matters in Modern Neuroimaging

In the era of high-resolution MRI and AI-assisted radiology, rare sellar and suprasellar tumors such as pituicytoma are increasingly recognized. Although classified as a WHO Grade 1 tumor, its diagnostic complexity and surgical challenges make it highly relevant for radiologists, neurosurgeons, and endocrinologists.

This article delivers a world-class, expert-level yet reader-friendly analysis of pituicytoma, based on the provided case and latest literature.

Case Presentation: MRI Findings and Clinical Context

Clinical History

A 39-year-old male presented with:

Low testosterone
Central hypogonadism
Growth hormone deficiency

This endocrine profile strongly suggests dysfunction of the hypothalamic-pituitary axis, prompting an MRI evaluation.

Figure 1. Sagittal MRI (T1 Pre/Post Contrast)

A well-defined suprasellar mass demonstrates an isointense signal on T1-weighted imaging, with progressive contrast enhancement. Notably, the posterior pituitary bright spot is absent, suggesting involvement of the neurohypophysis or infundibulum.

Figure 2. Coronal MRI (Dynamic Contrast Enhancement)

The lesion shows early peripheral enhancement followed by homogeneous filling, with less intense enhancement than the pituitary gland, helping distinguish it from a pituitary adenoma.

Figure 3. Axial MRI (T1 Postcontrast, T2, FLAIR)

The tumor appears T1 isointense and mildly T2 hyperintense, with no surrounding edema, indicating a non-aggressive, well-circumscribed lesion.

Figure 4. DWI and ADC Map

There is no diffusion restriction, supporting a low cellularity, benign tumor, consistent with WHO Grade 1 pathology.

Final Radiologic Diagnosis

Pituicytoma (Suprasellar Type)

Pathophysiology of Pituicytoma

Pituicytomas originate from pituicytes, specialized glial cells of the posterior pituitary (neurohypophysis) and infundibulum.

Key Molecular Features:

Expression of TTF-1 (Thyroid Transcription Factor-1)
Glial differentiation markers (e.g., S-100, GFAP variable)
Low proliferative index (Ki-67 typically <3%)

2022 WHO Classification Update:

Previously separate entities are now unified under the pituicytoma spectrum:

Classic pituicytoma
Granular cell tumor
Spindle cell oncocytoma
Sellar ependymoma

👉 This reflects a shared cellular origin and molecular profile.

Epidemiology

Extremely rare (<1% of sellar tumors)
Age: Typically 30–60 years
No strong gender predilection
Often incidentally discovered or misdiagnosed

Clinical Presentation

Common Symptoms:

Visual disturbance (optic chiasm compression)
Headache
Hypopituitarism (as in this case)
Hyperprolactinemia (stalk effect)

Rare Symptom:

Diabetes insipidus (very uncommon)

Imaging Features(High-Yield Radiology Insights)

MRI Characteristics

Feature	Description
Location	Suprasellar or combined intra-suprasellar
T1	Isointense
T2	Iso- to hyperintense
Enhancement	Strong, homogeneous (dynamic early enhancement)
DWI	No restriction
Pituitary Bright Spot	Absent
Stalk	Often obscured
Edema	Absent

Key Diagnostic Clues

Absence of the posterior pituitary bright spot
No dural tail sign (rules against meningioma)
Early homogeneous enhancement
Separate from the pituitary gland

Differential Diagnosis

1. Pituitary Adenoma

Usually sellar origin
Delayed enhancement
Causes sellar expansion

2. Papillary Craniopharyngioma

Solid suprasellar mass
Often BRAF mutation positive
May show cystic changes

3. Meningioma

Dural tail sign present
Strong homogeneous enhancement

4. Germinoma

Younger patients
May show diffusion restriction

Diagnosis Strategy

Step-by-Step Approach:

Identify location (suprasellar vs sellar)
Evaluate enhancement dynamics
Check the posterior pituitary bright spot
Assess diffusion characteristics
Correlate with endocrine findings

👉 Final confirmation requires histopathology

Treatment

Primary Treatment:

Surgical resection (gold standard)
- Transsphenoidal approach (preferred)
- Transcranial approach (large tumors)

Challenges:

Highly vascular tumor
Risk of incomplete resection

Adjuvant Therapy:

Radiotherapy (controversial, limited evidence)

Prognosis

Generally excellent (benign tumor)
Low recurrence if gross total resection is achieved
Requires long-term MRI follow-up

High-Value Clinical Insight

👉 The absence of the posterior pituitary bright spot + suprasellar solid mass is a critical diagnostic clue for pituicytoma.

Quiz

Q1. Where is the abnormality located?

A. Pineal gland
B. Pituitary sella
C. Prepontine cistern
D. Suprasellar cistern
E. Corpus callosum

✅ Answer: D. Suprasellar cistern. Explanation: MRI shows a well-circumscribed enhancing mass in the suprasellar region, separate from the pituitary gland.

Q2. Which imaging feature favors pituicytoma?

A. Dural tail sign
B. Diffusion restriction
C. Posterior pituitary bright spot preserved
D. Absence of posterior bright spot
E. Calcification

✅ Answer: D. Absence of posterior bright spot. Explanation: Loss of the neurohypophyseal bright spot suggests involvement of the posterior pituitary.

Q3. Which is NOT a posterior pituitary tumor?

A. Pituicytoma
B. Granular cell tumor
C. Spindle cell oncocytoma
D. Pituitary neuroendocrine tumor
E. Sellar ependymoma

✅ Answer: D. Pituitary neuroendocrine tumor. Explanation: Pituitary neuroendocrine tumors arise from the anterior pituitary, not the posterior lobe.

Conclusion

While rare, a pituicytoma is a critical diagnostic entity in neuroradiology. Recognizing its imaging signature—especially the absence of the posterior pituitary bright spot and suprasellar enhancement pattern—can significantly improve diagnostic accuracy.

Pituicytoma MRI Diagnosis: Suprasellar Tumor Imaging, Differential Diagnosis, and Treatment Strategy